Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery

DISEASE CHARACTERISTICS: Inclusion criteria: * Histologically confirmed metastatic colorectal adenocarcinoma * Bidimensionally measurable metastatic disease limited to the liver and considered curatively resectable after response to systemic therapy as assessed by a surgical board * Additional metastatic disease to the lungs consisting of no more than 3 potentially resectable lesions allowed * Must have at least one lesion of 30 mm or less Exclusion criteria: * History or evidence upon physical examination of CNS disease unless adequately treated (e.g., uncontrolled seizure with standard medical therapy or history of stroke) PATIENT CHARACTERISTICS: Inclusion criteria: * Performance status ≤ 1 * Life expectancy \> 12 weeks * WBC ≥ 3,000/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Creatinine 1.25 x upper limit of normal (ULN) * Bilirubin 1.25 x ULN (1.5 x ULN if liver metastasis) * AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver metastasis) * Woman and men of childbearing age must use adequate contraception Exclusion criteria: * Pregnancy (positive serum pregnancy test) or lactation * Chronic diarrhea ≥ grade 2 * Other serious illness or medical condition including any of the following: * Unstable cardiac disease requiring treatment * Congestive heart failure or angina pectoris even if medically controlled * Significant arrhythmias * History of significant neurologic or psychiatric disorders including psychotic disorders, dementia, or seizures that would prohibit the understanding and giving of informed consent * Active uncontrolled infection * Severe hypercalcemia * Other serious underlying medical condition that could impair the ability of the patient to participate in the study * Neuropathy \> grade 1 of any etiology * Known DPD deficiency * Known severe polyneuropathy * Known allergy to Chinese hamster ovary cell proteins, other recombinant human or humanized antibodies, any excipients of bevacizumab formulation, or any other study drugs * Chronic inflammatory bowel disease * Acute or subacute intestinal occlusion * History of previous arterial thromboembolism * Uncontrolled hypertension * Evidence of bleeding diathesis or coagulopathy * Serious nonhealing wound, ulcer, or bone fracture * History of tumor other than basocellular carcinoma of the skin * Peripheral neuropathy \> grade 1 of any origin (e.g., alcohol) * Significant traumatic injury within 28 days prior to study treatment PRIOR CONCURRENT THERAPY: Exclusion criteria: * No prior chemotherapy for metastatic disease * Prior adjuvant chemotherapy permitted if interval since last treatment administration and recurrence is \> 6 months * Major surgical procedure or open biopsy within 28 days prior to study treatment or anticipation of the need for major surgical procedure during the course of the study * Treatment in a clinical trial within 30 days prior to study entry * Concurrent treatment with other experimental drugs or other anticancer therapy * Current or recent use (within 10 days prior to study treatment) of full-dose oral or parenteral anticoagulants for therapeutic purposes * Chronic daily treatment with aspirin (\> 325 mg/day)